#### ORIGINAL RESEARCH

# Clinical significance of systemic immuneinflammation index (SII) and C-reactive proteinto-albumin ratio (CAR) in patients with esophageal cancer: a meta-analysis

This article was published in the following Dove Press journal: Cancer Management and Research

Yi Zhang Guoliang Xiao Rong Wang

Department of General Surgery, the First People's Hospital of Neijiang, Neijiang, Sichuan 641000, People's Republic of China

Background: Numerous studies have reported that systemic immune-inflammation index (SII) and C-reactive protein-to-albumin ratio (CAR) correlate with tumor progression and prognosis in various types of human cancer. The aim of this study is to systematically investigate the clinical significance of SII and CAR in esophageal cancer (EC).

Methods: We searched a number of databases for articles reporting the effect of pretreatment SII and CAR on the survival of EC patients. Review Manager 5.3 and STATA/SE 14.1 were applied in this meta-analysis. The multivariable-adjusted hazard ratio (HR) was used for calculating the relationship between SII and CAR and overall survival (OS), and the odds ratio (OR) was applied for the clinical pathology.

Results: Five original studies for SII and seven original datasets for CAR were included for analysis. Increased SII showed a significant association with shorter OS in EC patients after surgery (HR: 1.34, 95% CI: 1.15–1.53, P<0.001) and high CAR indicated worse long-term OS in EC (HR: 1.60, 95% CI: 1.29–1.90, P<0.001). Different subgroup analyses were also confirmed the prognostic roles in EC patients. Furthermore, the adverse impacts of elevated SII and CAR on tumor progression were revealed in the infiltration depth, lymph node metastasis, and clinical stage.

**Conclusions:** Both pretreatment SII and CAR might be promising predictors of cancer survival and tumor progression in EC. Further studies are warranted to verify the clinical usefulness in patients with EC.

Keywords: systemic immune-inflammation index, C-reactive protein-to-albumin ratio, esophageal cancer, prognosis, clinical pathology, meta-analysis

# Introduction

Esophageal cancer (EC) is the sixth major cause of cancer-related death globally, and esophageal squamous cell carcinoma (ESCC) is the predominant pathological subtype worldwide.<sup>1,2</sup> Above half of all diagnosed EC cases occurred in Asian countries and the five-year survival rates for the patients with this disease are still low and unsatisfactory.<sup>3,4</sup> Prognosis-related indicators could contribute to prognostic assessment as well as individualized treatment. Thus, searching for prognostic indicators that are non-invasive and easily-available is significant and required for clinical practice.

Department of General Surgery, the First People's Hospital of Neijiang, Yuzhong Road, Shizhong District, Neijiang, Sichuan 641000, People's Republic of China Tel +861 528 212 8759 status were involved in tumor development and considered as important factors Email 3455647525@qq.com



Correspondence: Yi Zhang

© 2019 Zhang et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

Increasing evidence has shown systemic inflammatory responses and nutritional

associated with clinical prognosis in various types of cancers.<sup>5–8</sup> And therefore a series of biological indicators based on inflammatory and/or nutritional status have been reported as tumor biomarkers.<sup>9-11</sup> Among them, systemic immune-inflammation index (SII), defined as neutrophil × platelet/lymphocyte, was initially known as an indicator of the host inflammatory status as well as a prognostic marker in hepatocellular carcinoma.<sup>12</sup> And the good prognostic value of SII was subsequently reported in EC and other tumors.<sup>13,14</sup> Another inflammation-based score, C-reactive protein-to-albumin ratio (CAR), based on C-reactive protein and albumin, also aroused great concern in the prediction in multiple tumors, including EC.<sup>15–17</sup> And different cutoffs of these two parameters have been utilized in previous studies to display the predictive values in cancer patients.<sup>13–16</sup>

However, the relationships between pretreatment SII and CAR and clinical outcomes of EC are inconsistent, their values as prognostic tumor markers in EC remain elusive. And to the best of our knowledge, no meta-analysis regarding the clinical significance of both SII and CAR in EC patients is available. Therefore, we searched all relevant literature to perform an integrated meta-analysis to fully address the clinical values of SII and CAR in EC sufferers. According to PICOS principles, the participants with primary EC were included, and we compared the related clinical outcomes in EC patients with high SII/ CAR and those with low SII/CAR. Any studies designed that in compliance with screening criteria were considered eligible and collected for further analysis.

# Materials and methods

In this study, we performed the meta-analysis based on the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement.

# Search strategy and study selection

Two authors searched eligible articles independently in PubMed, Web of Science, Embase, Cochrane Library databases and Google Scholar from the inception of the databases to September 1, 2018. The search was restricted to the English language. The following keywords and their combinations were used in searching: "carcinoma" or "cancer" or "tumor", and "esophageal", and "systemic immune-inflammation index" or "SII", or "C-reactive protein-to-albumin ratio" or "CAR" or "C-reactive protein/ albumin". The detailed search strategy was illustrated in the **Supplementary materials section**. Additionally, the references in the eligible publications were also reviewed for potential studies.

# Selection criteria

Published articles were included in this meta-analysis if they met the following criteria: 1) All patients collected were histopathologically confirmed to be primary esophageal cancer; 2) The SII and/or CAR were measured prior to treatment; 3) The hazard ratios (HRs) with their 95% confidence interval (95% CI) were reported in multivariate analysis; 4) Original articles were published in English; 5) Only the most complete data were included if overlapping data were found in more than one study. Any studies that were reviews, abstracts, conferences, or posters are excluded in this meta-analysis.

# Data extraction

For each study, the following information was extracted by two authors: the name of first author, year of publication, country, study type, pathological type, included period, number of patients, age distribution, end-point, follow-up time, cut-off selection, treatments, stage of cancer, cutoff values and HRs with the 95% CIs. Furthermore, the number of patients for the clinical pathology (including tumor grade, infiltration depth, lymph node metastasis, and clinical stage) was directly extracted from the eligible studies.

# Quality assessment

Two authors independently assessed the quality of each study in the meta-analysis, we used the method that was detailed described in the study by Perisanidis et al<sup>18</sup> It contained a total of eight items, and each study included in this meta-analysis could get a final score ranged from 0 to 8 after quality assessment.

# Statistical analysis

The risk of bias summary and risk of bias graph were applied using Review Manager 5.3, and the data analyses were performed with STATA/SE 14.1 in this meta-analysis. The cohort-specific HRs and 95% CIs for cancer survival were extracted from multivariate cox proportional hazard models. In addition, subgroup analysis was conducted to explore the prognostic values of SII and CAR in EC patients. And for the associations between SII/CAR and clinicopathologic characteristics in EC cases, the pooled ORs and 95% CIs were evaluated using STATA/ SE 14.1. Cochran's Q test and Higgins I square were used to determine the statistical heterogeneity across studies.  $I^2>50\%$  or P<0.1 was considered as heterogeneity, then a random-effects model was used. Otherwise, a fixed-effects model was utilized to combine the data when there was no significant heterogeneity. Publication bias was assessed by Begg's funnel plot and Begg's test. And the sensitivity analysis was utilized by omitting individual study one-by-one to assess the robustness of the results. And *P*-value less than 0.05 was considered statistically significant.

# Results

## Literature characteristics

After primary retrieval, a total of 210 relevant articles were incorporated into our initial assessment after exclusion of the duplications, and then 189 articles were further excluded by screening the titles and abstracts. The remaining 21 full-text articles were assessed for eligibility. Among them, 10 articles were further removed with the following reasons: such as HRs were not reported in multivariate analysis, no survival data available, and SII/CAR was measured after treatment. Finally,11 published articles were included in this meta-analysis.<sup>14,16,19–27</sup> Among them, 4 articles were for SII, 6 articles were for CAR, and 1 article was for both SII and CAR. The process of identifying studies is shown in Figure 1.

For the relationship between SII and survival rate in EC patients, five cohort studies were collected with a total of 2292 cases. Among them, four studies were published in 2017 or later and one study was published before 2017. All these studies assessed patients from East Asian countries (China and Japan), and the endpoints of OS and CSS were addressed in 4 studies and 1 study, respectively, and the CSS was integrated into the meta-analysis of OS. In terms of pathological types, 4 articles reported ESCC, 1 article studied the mixture of ESCC, EAC, and others. The cut-off value of SII varied in different studies, ranging from 307 to 650 with a mean of 462.

For the correction of CAR in EC patients, 7 studies selected for analysis comprised 1742 patients, with sample sizes ranging from 116 to 468 patients. Among them, 2 studies were published in 2015, 2 articles were released in 2017, and 3 studies were published in 2018. 1 study assessed patients from Australia and the rest 6 were conducted in East Asian populations (China and Japan). All the studies assessed the correction of CAR with OS. In terms of pathological types, 5 studies worked on ESCC, 1 studies focused on the mixture of ESCC and EAC, and another one study worked on the mixture of ESCC, EAC, and other types. There was a wide range of the cut-off value of CAR, ranging from 0.023 to 0.95 with the mean of 0.277.



Figure I Flow diagram of included studies for this meta-analysis.

And the relevant data of clinicopathologic characteristics for SII and CAR, including tumor grade, infiltration depth, lymph node metastasis, and clinical stage are shown in Table S1. The quality of the 12 included cohort studies was good with an average quality score of 7 (range 5–8, Figure 2, Table S2). In addition, the risk of bias summary and risk of bias graph for SII and CAR were presented in Figures S1 and Figure S2, respectively. The main characteristics of all cohort studies are summarized in Table 1.

# SII in esophageal cancer

### Overall survival (OS)

Five studies with a total of 2292 cases explored the effect of SII on OS in esophageal cancer. As no obvious heterogeneity observed among studies, the fixed effects model was used (I<sup>2</sup>=16.0%, p<sub>het</sub>=0.312). The pooled results indicated that high SII was significantly related with shorter OS in EC patients following surgery (HR: 1.34, 95% CI: 1.15–1.53, *P*<0.001; Figure 3).

As shown in Table 2, when stratified by the pathological type, high SII had a significantly worse OS in ESCC (HR: 1.34, 95% CI: 1.14–1.53, P<0.001). In addition, statistically significant pooled multivariable adjusted HR values >1 were consistently calculated in subgroup metaanalyses stratified by cut-off value ( $\geq$ 462 vs <462), followups ( $\geq$ 5 years vs <5 years) and cancer staging (Non-metastatic vs < Mixed).

#### Clinical pathology

*Histological grade.* Five articles with 2,292 patients coved the effect of high SII on histological grade. The fixed effect model was used ( $I^2=10.0\%$ ,  $P_{het}=0.349$ ), the combined results showed that there was no significant difference between SII status and histological grade (OR: 1.07, 95% CI: 0.87–1.30, *P*=0.528; Figure 4A).

Infiltration depth. Four studies, consisting of 1,994 patients, explored the relationship between SII and depth of tumor invasion. The pooled analysis revealed the pooled OR of 2.10 with 95% CI: 1.72–2.56 (P<0.001) (Figure 4B) with no significant heterogeneity ( $I^2$ =42.4%, P<sub>het</sub>=0.157). Patients with high SII have deeper infiltration depth when compared with those with low SII.

*Lymph node metastasis.* A total of four studies with 1,994 patients reported the relationship between SII and lymph node metastasis. As shown in Figure 4C, the random effect model was used ( $I^2$ =60.8%,  $P_{het}$ =0.054), the patients with esophageal cancer were at significantly greater risk of lymph node metastasis (OR: 1.51, 95% CI: 1.09–2.09, P<0.001).

*Clinical stage.* Five studies selected comprised 2,292 patients assessed the association between SII and clinical stage. The estimated proportion of heterogeneity ( $I^2$ ) between five SII studies was 50.4% (*P*=0.089), the random effect model was applied. As indicated in Figure 4D, high SII was correlated with the advanced clinical stage in patients with esophageal cancer (OR: 2.00, 95% CI: 1.51–2.65, *P*<0.001).



Figure 2 Quality assessment of 12 cohort studies included in the meta-analysis according to predefined eight items.

Table	I Main char	acteristics of all ir	ncluded studi	se										
	Study/	Pathological	Country	Study	Included	No. of	Age	Outcomes	Follow-	Cutoff	Cut-off	Treatment	Stage	MVA
	Year	type		type	period	sample	(years)		dn	value	selection	methods		
SII	Geng Y,	ESCC	China	Я	2002–2012	916	median:	SO	≥5 years	307	X-tile	With-surgery	Non-	Yes
	2016 <sup>14</sup>						60				software		metastatic	
	Feng JF,	ESCC	China	ĸ	2005 -2008	298	AA	CSS	≥5 years	410	Cutoff	With-surgery	Non-	Yes
	2017 <sup>16</sup>										Finder		metastatic	
	Wang L,	ESCC	China	ĸ	2012.1-	280	mean:	SO	<5 years	560	ROC	With-surgery	Mixed	Yes
	2017 <sup>19</sup>				2012.12		64.I				analysis			
	Ishibashi	ESCC/EAC/	Japan	ĸ	2009–2014	143	mean:	SO	≥5 years	650	ROC	With-surgery	Mixed	Yes
	Υ, 2018 <sup>20</sup>	Others					70.6				analysis			
	Zhang H,	ESCC	China	ĸ	2005 -2013	655	median:	SO	≥5 years	387.65	ROC	With-surgery	Non-	Yes
	2018 <sup>21</sup>						61				analysis		metastatic	
CAR	Wei XL,	ESCC	China	ĸ	2006–2010	423	median:	SO	≥5 years	0.095	ROC	Mixed	Mixed	Yes
	2015 <sup>22</sup>						58				analysis			
	Xu XL,	ESCC	China	2	2000-2010	468	median:	SO	≥5 years	0.5	ROC	With-surgery	Non-	Yes
	2015 <sup>23</sup>						58				analysis		metastatic	
	Otowa Y,	ESCC	Japan	ĸ	2007–2014	149	mean:	SO	≥5 years	0.03	ROC	With-surgery	Non-	Yes
	2017 <sup>24</sup>						66.9				analysis		metastatic	
	Jomrich	ESCC/EAC	Austria	ĸ	2003-2014	283	mean:	SO	≥5 years	0.95	٨٨	With-surgery	Mixed	Yes
	G, 2017 <sup>25</sup>						63							
	Ishibashi	ESCC/EAC/	Japan	ч	2009–2014	143	mean:	SO	≥5 years	0.3	ROC	With-surgery	Mixed	Yes
	Υ, 2018 <sup>20</sup>	Others					70.6				analysis			
	Kunizaki	ESCC	Japan	2	2007-2014	116	mean:	SO	≥5 years	0.042	ROC	Mixed	Mixed	Yes
	M, 2018 <sup>26</sup>						66				analysis			
	Yu X,	ESCC	China	2	2005-2012	160	median:	SO	≥5 years	0.023	ROC	With-surgery	Non-	Yes
	2018 <sup>27</sup>						59				analysis		metastatic	
Abbrev not avail	<b>iations:</b> R, retr <sup>i</sup> able.	ospective; ESCC, esoph	ageal squamous c	ell carcinom:	a; EAC, esophagea	l carcinoma; C	)S, overall surv	vival; CSS, cancer-sl	pecific survival;	MVA, multivar	iate analysis. RO	C, receiver operating	g characteristic o	urve; NA,

\_\_\_\_\_

4189



Figure 3 Meta-analysis of the correlation between SII and OS.

Abbreviations: OS, overall survival; SII, systemic immune-inflammation index; HR, hazard ratio; 95% CI, 95% confidence interval.

Table	2	Subgroup	analysis	of	the	correlation	between	SII	and	OS
	_	• • • • • • • • • • • • • • • • • • •		••••				••••		

Subgroup factor	No. of studies	Pooled HR (95% CI)	P-value	Heterogeneity	/
				l <sup>2</sup> (%)	P <sub>het</sub>
Pathological type					
ESCC	4	1.34(1.14–1.53)	<0.001	35.1	0.202
Mixed	1	1.64(0.74–3.96)	NS	-	-
Cut-off value					
≥462	2	2.23(1.26-3.21)	<0.001	0.0	0.367
<462	3	1.30(1.11–1.50)	<0.001	0.0	0.735
Follow-ups					
≥5 years	4	1.31(1.11–1.50)	<0.001	0.0	0.853
<5 years	1	2.58(1.62-4.09)	<0.001	-	
Clinical stage					
Non-metastatic	3	1.30(1.11–1.50)	<0.001	0.0	0.735
Mixed	2	2.23(1.26-3.21)	<0.001	0.0	0.367

Abbreviations: ESCC, esophageal squamous cell carcinoma; HR, hazard ratio; 95%CI, 95% confidence interval; NS: not significant.

# CAR in esophageal cancer

Overall survival (OS)

A total of 1,742 cases from seven articles reported the effect of CAR on OS in esophageal cancer. The fixed effects model was used for no obvious heterogeneity ( $I^2=35.7\%$ ,  $P_{het}=0.155$ ). The combined results showed that patients with elevated CAR were expected to suffer worse long-term OS (HR: 1.60, 95% CI: 1.29–1.90, P<0.001; Figure 5).

As summarized in Table 3, when stratified by the pathological type, CAR could be a significant prognostic

biomarker in ESCC (HR: 1.64, 95% CI: 1.30–1.98, P<0.001). In addition, significant associations between high CAR level and poor OS were also found in the subgroup analyses of cut-off value ( $\geq$ 0.277 vs <0.277), treatments methods (With-surgery vs Mixed) and clinical staging (Non-metastatic vs Mixed).

#### Clinical pathology

*Histological grade.* A total of four articles with 1,193 patients reported the relationship between CAR and histological grade. The pooled results indicated that no significant association was observed between CAR and



Figure 4 Meta-analysis of the relationship between SII and clinical pathology in EC patients: A) histological grade; B) infiltration depth; C) lymph node metastasis; D) clinical stage. Abbreviations: SII, systemic immune-inflammation index; EC, esophageal cancer; OR, odds ratio; 95%CI, 95% confidence interval.



Figure 5 Meta-analysis of the correlation between CAR and OS.

Abbreviations: OS, overall survival; CAR, C-reactive protein-to-albumin ratio; HR, hazard ratio; 95%Cl, 95% confidence interval.

Table 3	<b>3</b> Subgroup	analysis	of	the	correlation	between	CAR	and	OS
---------	-------------------	----------	----	-----	-------------	---------	-----	-----	----

Subgroup factor	No. of studies	Pooled HR(95% CI)	P-value	Heterogeneity	,
				l <sup>2</sup> (%)	P <sub>het</sub>
Pathological type					
ESCC	5	1.64(1.30–1.98)	<0.001	47.8	0.104
Mixed	2	1.43(0.73–2.12)	NS	27.5	0.240
Cut-off value					
≥0.277	3	1.92(1.42-2.42)	<0.001	62.3	0.070
<0.277	4	1.41(1.02–1.80)	<0.001	0.0	0.668
Treatments					
With-surgery	5	1.78(1.33-2.23)	<0.001	43.6	0.131
Mixed	2	1.45(1.03–1.86)	<0.001	9.7	0.293
Clinical stage					
Non-metastatic	3	2.04(1.44-2.64)	<0.001	50.0	0.135
Mixed	4	1.44(1.09–1.80)	<0.001	0.0	0.477

Abbreviations: ESCC, esophageal squamous cell carcinoma; HR, hazard ratio; 95%Cl, 95% confidence interval; NS: not significant.



Figure 6 Meta-analysis of the relationship between CAR and clinical pathology in EC patients: (A) histological grade; (B) infiltration depth; (C) lymph node metastasis; (D) clinical stage. Abbreviations: CAR, C-reactive protein-to-albumin ratio; EC, esophageal cancer; OR, odds ratio; 95%CI, 95% confidence interval.

histological grade (OR: 1.26, 95% CI: 0.69–2.32, P=0.456; random-effects; Figure 6A)

overall results showed that the patients with high CAR more likely to have deeper tumor invasion (OR: 2.42, 95% CI: 1.48-3.98, P<0.001)

*Infiltration depth.* Four articles with 1,088 patients reported the correlation between CAR and infiltration depth. As shown in Figure 6B, significant heterogeneity was observed ( $I^2$ =56.0%,  $P_{het}$ =0.078; random-effects), the

*Lymph node metastasis.* Only three articles with 972 cases coved the correlation of high CAR on lymph node metastasis. The fixed effect model was employed

 $(I^2=21.7\%, P_{het}=0.279)$ , the combined analysis revealed the pooled OR of 1.83 with 95% CI: 1.34–2.49 (*P*<0.001) (Figure 6C), suggesting that high CAR was significantly associated with lymph node metastasis.

*Clinical stage*. Four articles, consisting of 1,150 patients, explored the association between CAR and clinical stage. No obvious heterogeneity was found, the fixed effect model was utilized ( $I^2=0.0\%$ ,  $P_{het}=0.788$ ). As indicated in Figure 6D, the patients with high CAR tended to have advanced tumor stages compared those with low CAR (OR: 2.90, 95% CI: 2.20–3.81, *P*<0.001).

## Publication bias

The Begg's funnel plots were shown in Figure 7, and the *P*-values of Begg's were 0.086 for SII and 1.000 for CAR. These results showed that there was no publication bias in the current study.

## Sensitivity analysis

The sensitivity analysis indicated that the results of the combined analysis were robust (Figure 8).

# Discussion

Serum biological markers are considered non-invasive and obtained easily in daily clinical practice. Nowadays, many blood-related parameters, including lymphocyte count, plasma fibrinogen and albumin, have been reported as prognostic markers in various malignant tumors.<sup>28–31</sup> But a single blood indicator is often not stable and reliable for they are inevitably susceptible to many other factors. And some comprehensive index based on two or three hematological parameters have been identified, such as platelet to lymphocyte ratio (PLR), monocyte/lymphocyte ratio (MLR) and neutrophil/lymphocyte ratio (NLR), they all showed the potential prognosis prediction in multiple cancers.<sup>32–35</sup>

SII, as a combination of three blood-related factors, neutrophil, platelet, and lymphocyte, was shown to be related with prognosis in upper gastrointestinal (GI) cancers. For example, some researchers have reported that SII might be a useful indicator in predicting survival and clinicopathologic characteristics in patients with gastric cancer.<sup>13,36,37</sup> In addition, SII has shown to be superior to PLR, NLR, and MLR as a predictive biomarker in ESCC.<sup>14,16</sup> And CAR, based on serum C-reactive protein and albumin, was also revealed the great usefulness as a predictor of survival in various types of tumors, including upper GI cancers. A number of studies have indicated that preoperative high CAR was related with poor prognosis of patients with gastric cancer,<sup>38-41</sup> and also could act as a predictor for short-term complications in gastric cancer patients following gastrectomy.<sup>42</sup> And the prognostic values of CAR were also found in the patients with EC.<sup>19,20</sup>



Figure 7 Publication bias assessment for OS with SII (A) and CAR (B). Abbreviations: OS, overall survival; SII, systemic immune-inflammation index; CAR, C-reactive protein-to-albumin ratio.



Figure 8 Sensitivity analysis for OS in SII (A) and CAR (B).

Abbreviations: OS, overall survival; SII, systemic immune-inflammation index; CAR, C-reactive protein-to-albumin ratio.

SII and CAR, they are both nutrition and inflammationbased indexes although they are based on different serum parameters. The data of these serum factors can be available in routine blood tests, and they are cheap, non-invasive, and easily accessible. And the two indexes could better reflect systemic inflammatory response and also showed better predictive performance in tumors. As yet, until now, there are no studies that comprehensively assess the prognostic and clinicopathological roles of both SII and CAR in cancer of the esophagus. In order to provide new insights that helping understanding the clinical values of SII and CAR in EC patients, a total of twelve original datasets were included to demonstrate the relationship between SII/CAR and clinical relevance in oesophageal cancer. The combined results showed that high pretreatment SII/CAR was significantly associated with worse clinical outcomes in EC patients.

Our study is the first meta-analysis to evaluate the clinical roles of both SII and CAR in EC patients. We found that high pretreatment SII and CAR were closely related to worse clinical outcomes in EC. Both high pretreatment SII and CAR were significantly related to shorter OS in EC patients. And the subgroup meta-analyses also further confirmed the clinical roles of these two indexes in this disease. As for the relationships between SII or CAR and clinical pathological factors in EC, we found that elevated SII and CAR were significantly related with deeper infiltration depth, positive lymph node metastasis, and advanced clinical stage.

Nevertheless, there exist some limitations to our study. First, the total number of included studies were still relatively small and only the articles published in English were searched. Second, the included studies conducted in Asian countries are the majority, which might entail the preferences of the population. Third, most of the studies focused on the prognostic roles of these two indexes on ESCC, as the difference in the pathology of EAC, their prognosis prediction on EAC need further validated. Fourth, there were a diversity of cut-off values that were used to divide the patients into high and low SII/CAR groups. Additionally, many other factors, such as postoperative treatment, tumor stage, they could also affect the survival time of the patients.

In conclusion, our study provides clear evidence that both SII and CAR are correlated with clinical outcomes in EC and could be used as a noninvasive prognostic marker for this disease. In this meta-analysis, the cut-off values for SII (462) and CAR (0.277) are recommended that would be useful for predicting outcomes. Given the limitations mentioned, further larger multi-center studies are required to further confirm our findings.

# Disclosure

The authors report no conflicts of interest in this work.

# References

- Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á. Esophageal cancer: risk factors, screening and endoscopic treatment in Western and Eastern countries. *World J Gastroenterol*. 2015;21 (26):7933–7943. doi:10.3748/wjg.v21.i26.7933
- Alsop BR, Sharma P. Esophageal Cancer. Gastroenterol Clin North Am. 2016;45(3):399–412. doi:10.1016/j.gtc.2016.04.001
- Codipilly DC, Qin Y, Dawsey SM, et al. Screening for esophageal squamous cell carcinoma: recent advances. *Gastrointest Endosc*. 2018;88(3):413–426. doi:10.1016/j.gie.2018.04.2352
- Ohashi S, Miyamoto S, Kikuchi O, et al. Recent advances from basic and clinical studies of esophageal squamous cell carcinoma. *Gastroenterology*. 2015;149(7):1700–1715. doi:10.1053/j.gastro.2015.08.054
- Diakos CI, Charles KA, McMillan DC, et al. Cancer-related inflammation and treatment effectiveness. *Lancet Oncol.* 2014;15(11):e493– e503. doi:10.1016/S1470-2045(14)70263-3
- Soria-Valles C, López-Soto A, Osorio FG, et al. Immune and inflammatory responses to DNA damage in cancer and aging. *Mech Ageing Dev.* 2017;165(Pt A):10–16. doi:10.1016/j.mad.2016.10.004
- Bail J, Meneses K, Demark-Wahnefried W. Nutritional status and diet in cancer prevention. *Semin Oncol Nurs.* 2016;32(3):206–214. doi:10.1016/j.soncn.2016.05.004
- Toles M, Demark-Wahnefried W. Nutrition and the cancer survivor: evidence to guide oncology nursing practice. *Semin Oncol Nurs*. 2008;24(3):171–179. doi:10.1016/j.soncn.2008.05.005
- Zhang Y, Wang L, Lin S, et al. Preoperative albumin-to-globulin ratio as a significant prognostic indicator in urologic cancers: a meta-analysis. *Cancer Manag Res.* 2018;10:4695–4708. doi:10.2147/CMAR.S178271
- Zhang Y, Zhang X. Prognostic value of aspartate aminotransferase to platelet ratio index as a noninvasive biomarker in patients with hepatocellular carcinoma: a meta-analysis. *Cancer Manag Res.* 2018;10:3023–3032. doi:10.2147/CMAR.S174095
- Li YJ, Yang X, Zhang WB, et al. Clinical implications of six inflammatory biomarkers as prognostic indicators in Ewing sarcoma. *Cancer Manag Res.* 2017;9:443–451. doi:10.2147/CMAR.S146827
- Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. *Clin Cancer Res.* 2014;20(23):6212–6222. doi:10.1158/1078-0432.CCR-14-0442
- 13. Chen L, Yan Y, Zhu L, et al. Systemic immune-inflammation index as a useful prognostic indicator predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy. *Cancer Manag Res.* 2017;9:849–867. doi:10.2147/CMAR.S151026
- 14. Geng Y, Shao Y, Zhu D, et al. Systemic immune-inflammation index predicts prognosis of patients with esophageal squamous cell carcinoma: a propensity score-matched analysis. *Sci Rep.* 2016;6:39482. doi:10.1038/srep39482
- Deng TB, Zhang J, Zhou YZ, et al. The prognostic value of Creactive protein to albumin ratio in patients with lung cancer. *Medicine (Baltimore)*. 2018;97(50):e13505. doi:10.1097/MD.00000 00000013505
- Feng JF, Chen S, Yang X. Systemic immune-inflammation index (SII) is a useful prognostic indicator for patients with squamous cell carcinoma of the esophagus. *Medicine (Baltimore)*. 2017;96(4): e5886. doi:10.1097/MD.000000000005886
- 17. Shimizu T, Ishizuka M, Suzuki T, et al. The value of the C-reactive protein-to-albumin ratio is useful for predicting survival of patients with child-pugh class A undergoing liver resection for hepatocellular carcinoma. *World J Surg.* 2018;42(7):2218–2226. doi:10.1007/ s00268-017-4446-0
- Perisanidis C, Psyrri A, Cohen EE, et al. Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors: a systematic review and meta-analysis. *Cancer Treat Rev.* 2015;41(10):960–970. doi:10.1016/j.ctrv.2015.10.002

- Wang L, Wang C, Wang J, et al. A novel systemic immune-inflammation index predicts survival and quality of life of patients aftercurative resection for esophageal squamous cell carcinoma. *J Cancer Res Clin Oncol*. 2017;143(10):2077–2086. doi:10.1007/s00432-017-2451-1
- 20. Ishibashi Y, Tsujimoto H, Hiraki S, et al. Prognostic value of preoperative systemic immunoinflammatory measures in patients with esophageal cancer. *Ann Surg Oncol.* 2018;25(11):3288–3299. doi:10.1245/s10434-018-6651-y
- 21. Zhang H, Shang X, Ren P, et al. The predictive value of a preoperative systemic immune-inflammation index and prognostic nutritional index in patients with esophageal squamous cell carcinoma. *J Cell Physiol.* 2018. doi:10.1002/jcp.27052 [[Epub ahead of print]].
- 22. Wei XL, Wang FH, Zhang DS, et al. A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the Creactive protein/albumin ratio. *BMC Cancer.* 2015;15:350. doi:10.1186/s12885-015-1584-3
- 23. Xu XL, Yu HQ, Hu W, et al. A novel inflammation-based prognostic score, the C-Reactive Protein/Albumin Ratio predicts the prognosis of patients with operable esophageal squamous cell carcinoma. *PLoS One.* 2015;10(9):e0138657. doi:10.1371/journal. pone.0138657
- 24. Otowa Y, Nakamura T, Yamamoto M, et al. C-reactive protein to albumin ratio is a prognostic factor for patients with cStage II/III esophageal squamous cell cancer. *Dis Esophagus*. 2017;30(12):1–5. doi:10.1093/dote/dox107
- 25. Jomrich G, Paireder M, Gleiss A, et al. Comparison of inflammationbased prognostic scores in a cohort of patients with resectable esophageal cancer. *Gastroenterol Res Pract.* 2017;2017:1678584. doi:10.1155/2017/1678584
- 26. Kunizaki M, Tominaga T, Wakata K, et al. Clinical significance of the C-reactive protein-to-albumin ratio for the prognosis of patients with esophageal squamous cell carcinoma. *Mol Clin Oncol.* 2018;8 (2):370–374. doi:10.3892/mco.2017.1527
- 27. Yu X, Wen Y, Lin Y, et al. The value of preoperative glasgow prognostic score and the C-Reactive protein to albumin ratio as prognostic factors for long-term survival in pathological T1N0 esophageal squamous cell carcinoma. *J Cancer*. 2018;9(5):807–815. doi:10.7150/jca.22755
- Wu Z, Zhang J, Cai Y, et al. Reduction of circulating lymphocyte count is a predictor of good tumor response after neoadjuvant treatment for rectal cancer. *Medicine (Baltimore)*. 2018;97(38):e11435. doi:10.1097/MD.000000000011435
- 29. Ji R, Ren Q, Bai S, et al. Prognostic significance of pretreatment plasma fibrinogen in patients with hepatocellular and pancreatic carcinomas: A meta-analysis. *Medicine (Baltimore)*. 2018;97(25): e10824. doi:10.1097/MD.000000000010824
- 30. Chen Z, Shao Y, Wang K, et al. Prognostic role of pretreatment serum albumin in renal cell carcinoma: a systematic review and metaanalysis. *Onco Targets Ther.* 2016;9:6701–6710. doi:10.2147/OTT. S108469
- Bozkaya Y, Erdem GU, Demirci NS, et al. Prognostic importance of the albumin to globulin ratio in metastatic gastric cancer patients. *Curr Med Res Opin.* 2018;35(2):1–8.
- Wang J, Zhou X, He Y, et al. Prognostic role of platelet to lymphocyte ratio in prostate cancer: A meta-analysis. *Medicine (Baltimore)*. 2018;97(40):e12504. doi:10.1097/MD.000000000012504
- 33. Wang W, Liu W, Zhang N, et al. Preoperative platelet-lymphocyte ratio is an independent prognostic factor in ampullary carcinoma following pancreaticoduodenectomy. *Oncol Lett.* 2018;16(4):4879– 4888. doi:10.3892/ol.2018.9285
- 34. Solmaz Medeni S, Acar C, Olgun A, et al. Can neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, and platelet-to-lymphocyte ratio at day +100 be used as a prognostic marker in multiple myeloma patients with autologous transplantation?. *Clin Transplant.* 2018;32(9):e13359. doi:10.1111/ctr.13359

- 35. Zhao Z, Zhao X, Lu J, et al. Prognostic roles of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in ovarian cancer: a meta-analysis of retrospective studies. *Arch GynecolObstet*. 2018;297(4):849–857. doi:10.1007/s00404-018-4678-8
- 36. Huang L, Liu S, Lei Y, et al. Systemic immune-inflammation index, thymidine phosphorylase and survival of localized gastric cancer patients after curative resection. *Oncotarget*. 2016;7(28):44185– 44193. doi:10.18632/oncotarget.9923
- Wang K, Diao F, Ye Z, et al. Prognostic value of systemic immuneinflammation index in patients with gastric cancer. *Chin J Cancer*. 2017;36(1):75. doi:10.1186/s40880-017-0243-2
- Liu X, Sun X, Liu J, et al. Preoperative C-Reactive Protein/Albumin Ratio predicts prognosis of patients after curative resection for gastric cancer. *Transl Oncol.* 2015;8(4):339–345. doi:10.1016/j. tranon.2015.06.006

- 39. Toyokawa T, Muguruma K, Tamura T, et al. Comparison of the prognostic impact and combination of preoperative inflammation-based and/ or nutritional markers in patients with stage II gastric cancer. *Oncotarget*. 2018;9(50):29351–29364. doi:10.18632/oncotarget.25486
- 40. Mao M, Wei X, Sheng H, et al. C-reactive protein/albumin and neutrophil/lymphocyte ratios and their combination predict overall survival in patients with gastric cancer. *Oncol Lett.* 2017;14(6):7417–7424. doi:10.3892/ol.2017.7179
- 41. Saito H, Kono Y, Murakami Y, et al. Prognostic significance of the preoperative ratio of C-Reactive protein to Albumin and neutrophillymphocyte ratio in gastric cancer patients. *World J Surg.* 2018;42 (6):1819–1825. doi:10.1007/s00268-017-4400-1
- 42. Sun F, Ge X, Liu Z, et al. Postoperative C-reactive protein/albumin ratio as a novel predictor for short-term complications following gastrectomy of gastric cancer. *World J Surg Oncol.* 2017;15(1):191. doi:10.1186/s12957-017-1258-5

# Supplementary materials



Figure SI Risk of bias assessment for SII. Abbreviations: SII, systemic immune-inflammation index.



Figure S2 Risk of bias assessment for CAR. Abbreviations: CAR, C-reactive protein-to-albumin ratio.

		פיר בוומו מריכיו ופנורט			3				
SII					CAR				
histological grade					histological grade				
	Poorly/undifferent	ciated	Well/Moderate			Poorly/undifferenti	ited	Well/Moderate	
Study	High SII	Low SII	High SII	Low SII	Study	High CAR	Low CAR	High CAR	Low CAR
Geng Y, 2016 <sup>14</sup>	306	114	357	139	Wei XL, 2015 <sup>22</sup>	66	93	81	183
Feng JF, 2017 <sup>16</sup>	43	15	174	66	Xu XL, 2015 <sup>23</sup>	23	62	64	318
Wang L, 2017 <sup>19</sup>	46	81	67	86	Ishibashi Y, 2018 <sup>20</sup>	13	7	62	61
Ishibashi Y, 2018 <sup>20</sup>	12	8	58	65	Yu X, 2018 <sup>27</sup>	21	31	64	44
Zhang H, 2018 <sup>21</sup>	77	37	328	213					
infiltration depth					infiltration depth				
	Т 3-4		T0-2			Т 3-4		TI-2	
Study	High SII	Low SII	High SII	Low SII	Study	High CAR	Low CAR	High CAR	Low CAR
Geng Y, 2016 <sup>14</sup>	377	106	286	147	Wei XL, 2015 <sup>22</sup>	88	174	27	87
Wang L, 2017 <sup>19</sup>	75	70	38	97	Xu XL, 2015 <sup>23</sup>	74	286	=	82
Ishibashi Y, 2018 <sup>20</sup>	52	31	81	42	Ishibashi Y, 2018 <sup>20</sup>	57	26	18	42
Zhang H, 2018 <sup>21</sup>	328	173	77	77	Kunizaki M, 2018 <sup>26</sup>	34	29	17	36
lymph node metastasis					lymph node metastasis				
Study	+ MN	- MN	+ MNJ	- MNJ		High CAR		Low CAR	
Geng Y, 2016 <sup>14</sup>	341	322	103	150	Study	+ MN	- MN	+ MNJ	- MN
Wang L, 2017 <sup>19</sup>	65	48	58	601	Wei XL, 2015 <sup>22</sup>	54	49	104	154
Ishibashi Y, 2018 <sup>20</sup>	42	28	41	32	Xu XL, 2015 <sup>23</sup>	69	8	228	153
Zhang H, 2018 <sup>21</sup>	184	221	105	145	Ishibashi Y, 2018 <sup>20</sup>	46	29	37	31
clinical stage					clinical stage				
	NI-III		0-11			NI-III		II-1	
Study	High SII	Low SII	High SII	Low SII	Study	High CAR	Low CAR	High CAR	Low CAR
Geng Y, 2016 <sup>14</sup>	271	82	392	171	Wei XL, 2015 <sup>22</sup>	97	104	50	172
Feng JF, 2017 <sup>16</sup>	107	81	011	63	Xu XL, 2015 <sup>23</sup>	66	197	21	184
Wang L, 2017 <sup>19</sup>	55	46	58	121	Ishibashi Y, 2018 <sup>20</sup>	47	30	28	38
Ishibashi Y, 2018 <sup>20</sup>	43	34	27	39	Kunizaki M, 2018 <sup>26</sup>	36	29	15	36
Zhang H, 2018 <sup>21</sup>	253	117	152	133					
Abbreviations: SII, systemic in	nmune-inflammation in	Idex; CAR, C-reactive	e protein-to-albumin	ratio; EC, esophage	al cancer; LNM, lymph node met	astasis.			

Table S1 Relevant data of clinicopathologic characteristics for SII and CAR in EC patients

Study <b>FReference]</b> * Geng Y, 2016 <sup>14</sup> Geng Y, 2016 <sup>14</sup> Vang L, Vang L, Vang L, 2017 <sup>19</sup> Ishibashi Y, 2017 <sup>19</sup> Col 8 <sup>20</sup> Zhang H, 2018 <sup>20</sup> Zhang H, 2018 <sup>20</sup> Zhang H, 2018 <sup>20</sup> Zhang H, 2018 <sup>21</sup> Wei XL, 2015 <sup>23</sup> Cova Y, 2015 <sup>23</sup> Orowa Y, 2015 <sup>23</sup> Orowa Y, 2015 <sup>23</sup> Orowa Y, 2015 <sup>23</sup> Orowa Y, 2015 <sup>23</sup> Orowa Y, 2015 <sup>24</sup> Orowa Y, 2015 <sup>23</sup> Orowa Y, 2015 <sup>20</sup> Orowa Y, 2015 <sup>20</sup> Chang H, 2015 <sup>20</sup> Chang H, 2015 <sup>20</sup> Chang H, 2015 <sup>20</sup> Chang H, 2015 <sup>20</sup> Chang H, 2018 <sup>20</sup> Orowa Y, 2018 <sup>20</sup> Orowa Y, 2015 <sup>20</sup> Orowa Y, 2015 <sup>21</sup> Orowa Y, 2015 <sup>20</sup> Orowa Y, 2015 <sup>20</sup> Oroma Y, 2015 <sup></sup>	Hypothesis and/or objective(s) stated yes yes yes yes yes yes	Tumor stage clearly described yes yes yes yes yes yes	<b>Clear</b> description of eligibility yes yes yes yes yes yes yes	Patients with inflammatory dis- ease or coagula- tion disorders excluded no yes yes yes no yes	Predictors and out- come(s) clearly no no no yes yes yes yes yes yes	Confounders considered in multivariate analysis yes yes yes yes yes yes	Follow-up period reported and long enough for outcomes to yes yes yes yes yes yes yes	Bias and limitations considered yes yes yes yes yes yes yes	Quality score (0 - 8) ( - 8) ( - 8) 8 8 8 8 8 8
17 <sup>25</sup> Iibashi Y,	yes	yes	. e	оц	yes	yes	yes	yes	6
118 <sup>20</sup> ınizaki M,	yes	yes	ę	оп	2	yes	yes	yes	2
18 <sup>20</sup> X 2018 <sup>27</sup>	ves	ves	ves	ves	ves	ves	ves	SAV	ω

Table S2 Study quality of all included cohort studies in the meta-analysis

Supplementary File 1. Literature search strategy in PUBMED

((((C-reactive[All Fields] AND protein-to-albumin[All Fields] AND ("Ratio (Oxf)"[Journal] OR "ratio"[All Fields])) OR ("automobiles"[MeSH Terms] OR "automobiles"[All Fields] OR "car"[All Fields])) OR (("c-reactive protein"[MeSH Terms] OR ("c-reactive"[All Fields] AND "protein"[All Fields]) OR "c-reactive protein"[All Fields] OR "c reactive protein"[All Fields]) AND ("albumins"[MeSH Terms] OR "albumins"[All Fields] OR "albumin"[All Fields]))) OR ((systemic[All Fields] AND immune-inflammation[All Fields] AND ("abstracting and indexing as topic"[MeSH Terms] OR ("abstracting" [All Fields] AND "indexing" [All Fields] AND "topic" [All Fields]) OR "abstracting and indexing as topic" [All Fields] OR "index" [All Fields])) OR ("Stat Interface" [Journal] OR "sii" [All Fields]))) AND (((("carcinoma" [MeSH Terms] OR "carcinoma" [All Fields]) OR ("neoplasms" [MeSH Terms] OR "neoplasms" [All Fields] OR "cancer" [All Fields])) OR ("tumour" [All Fields] OR "neoplasms" [MeSH Terms] OR "neoplasms" [All Fields] OR "tumor" [All Fields])) esophageal[All Fields]) AND ("0001/01/ AND 01"[PDAT]: "2018/09/01"[PDAT]) AND ("loattrfull text"[sb] AND English[lang])

#### **Cancer Management and Research**

Publish your work in this journal

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient.

Submit your manuscript here: https://www.dovepress.com/cancer-management-and-research-journal

#### **Dove**press

The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.